Financial Review: Nuwellis (NUWE) and The Competition

Nuwellis (NASDAQ: NUWE) is one of 65 publicly-traded companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare Nuwellis to related companies based on the strength of its analyst recommendations, valuation, earnings, dividends, profitability, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nuwellis and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuwellis 0 0 0 0 N/A
Nuwellis Competitors 211 883 1677 36 2.55

As a group, “Electromedical equipment” companies have a potential upside of 16.58%. Given Nuwellis’ competitors higher possible upside, analysts plainly believe Nuwellis has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Nuwellis and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nuwellis $7.44 million -$15.84 million -0.44
Nuwellis Competitors $999.91 million $94.29 million 136.92

Nuwellis’ competitors have higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

20.8% of Nuwellis shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 0.4% of Nuwellis shares are owned by insiders. Comparatively, 12.9% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Nuwellis has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Nuwellis’ competitors have a beta of 20.19, suggesting that their average share price is 1,919% more volatile than the S&P 500.


This table compares Nuwellis and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nuwellis -213.34% -86.10% -72.93%
Nuwellis Competitors -248.11% -29.16% -15.64%


Nuwellis competitors beat Nuwellis on 9 of the 10 factors compared.

About Nuwellis

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with's FREE daily email newsletter.